Latin America: How Regulatory Transparency Can Tackle Non-Comparable Biologics
Non-comparable biologics are a common problem in Latin America as they could deter companies with true biosimilars from entering the market. Among the solutions are better regulatory transparency and action to deal with “non-comparables” already on the market, says FIFARMA, the Latin American Federation of Pharmaceutical Industry.
You may also be interested in...
Proposal suggests condensing key data and findings into under 10 pages, published in English.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.